Understanding the detailed mechanism of altering the BCL-2/BCL-XL expression by high dose DHT will likely provide novel therapeutic approaches for improved bipolar androgen therapy of PCa. The gene discussed is BCL2L1; the disease is posterior cortical atrophy.